Off-label biologics use and infection risk—the great unknown

被引：0
|
作者：
Kevin L. Winthrop
Josef S. Smolen
机构：
[1] and Public Health and Preventive Medicine,Divisions of Infectious Diseases
[2] Oregon Health and Sciences University,Division of Rheumatology, Department of Medicine
[3] Medical University of Vienna,undefined
来源：
Nature Reviews Rheumatology | 2011年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The use of biologic therapies for off-label conditions in daily clinical practice is increasing, yet few studies have detailed the safety of these agents with regards to infection in patients with systemic autoimmune disease. New research offers a glimpse at the infection rates in these vulnerable patients.
引用
下载
收藏
页码：685 / 686
页数：1
相关论文
共 50 条
  • [1] THERAPY Off-label biologics use and infection risk-the great unknown
    Winthrop, Kevin L.
    Smolen, Josef S.
    NATURE REVIEWS RHEUMATOLOGY, 2011, 7 (12) : 685 - 686
  • [2] Documentation of off-label use of biologics in Rheumatoid Arthritis
    Furst, Daniel E.
    Fleischman, Roy
    Kalden, Joachim
    Kavanaugh, Arthur
    Sieper, Joachim
    Mease, Philip
    Smolen, Josef
    Breedveld, Ferrie
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 35 - 51
  • [3] Biologics in dermatology: Off-label indications
    Mitra, Debdeep
    Chopra, Ajay
    Saraswat, Neerja
    Mitra, Barnali
    Talukdar, Krishna
    Agarwal, Reetu
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2020, 11 (03) : 319 - 327
  • [4] RituximabUrinary tract infection and off-label use
    Reactions Weekly, 2024, 2016 (1) : 437 - 437
  • [5] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [6] Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study
    Maisonobe, Lucas
    Korganow, Anne-Sophie
    Berti, Alvise
    Deroux, Alban
    Dupin, Nicolas
    Aractingi, Selim
    Emmi, Giacomo
    Vandergheynst, Frederic
    Fabre, Marc
    Kluger, Nicolas
    Roux, Marielle
    Abisror, Noemie
    Benyamine, Audrey
    Cassone, Giulia
    Chasset, Francois
    Doutre, Marie-Sylvie
    Foucher, Aurelie
    Freguin, Caroline
    Gobert, Delphine
    Gombeir, Yannick
    Hernandez-Rodriguez, Jose
    Legouellec, Noemie
    Pinault, Anne-Lise
    Titeca-Beauport, Dimitri
    Jachiet, Marie
    Terrier, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1379 - 1380
  • [7] Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis
    Mettler, C.
    Durel, C. A.
    Guilpain, P.
    Bonnotte, B.
    Cohen-Aubart, F.
    Hamidou, M.
    Lega, J. C.
    Le Guern, V
    Lifermann, F.
    Poindron, V
    Pugnet, G.
    Servettaz, A.
    Puechal, X.
    Guillevin, L.
    Terrier, B.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 96 : 97 - 101
  • [8] Piperacillin/tazobactamCandida lipolytica infection and off-label use
    Reactions Weekly, 2024, 2008 (1) : 294 - 294
  • [9] Off-label use in cardiac surgery ["Off-label use" in der Herzchirurgie]
    Fenger H.
    Löher A.
    Sindermann J.R.
    Scheld H.H.
    Schmidt C.
    Hoffmeier A.
    Zeitschrift für Herz-,Thorax- und Gefäßchirurgie, 2009, 23 (6) : 345 - 348
  • [10] Thromboembolic events a risk in off-label use of rFVIIa
    Reactions Weekly, 2010, 1327 (1) : 2 - 2
12345